QL-325

N/A

Report date: 2026/03/19 17:15:02

Base Information

Drug NameQL-325
Drug Alias NameQL-325
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-C-Type lectin domain family 12 member A
TargetsT cell surface glycoprotein CD3C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co LtdQlsf Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesQlsf Biotherapeutics IncQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A